Clinical Trial

Feasibility of the Maastro Applicator in Rectal Cancer

Active, Not Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated August 14, 2025 (before its estimated April 2026 completion). Its status may not reflect the trial's current state.
Summary
The goal of this interventional pilot trial is to confirm that Maastro endoluminal HDR ( High Dose Radiation) contact brachytherapy boosting is feasible and may increase the chance of functional organ sparing of the rectum in patients with rectal cancer. Participants will be treated with chemoradiotherapy and an endoluminal boost with the Maastro applicator.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2023-10-13; most recent amendment 2025-08-11.
Status change: Not Yet Recruiting → Active, Not Recruiting 2025-08-11
Trial Details
NCT Number NCT06087718
Lead Sponsor Maastricht Radiation Oncology
Collaborators: Varian Medical Systems
Conditions Rectal Cancer, Feasibility, Toxicity, Quality of Life, Radiation Toxicity, Radiation Proctitis, Brachytherapy, Complete Response
Enrollment 10 participants
Start Date 2024-08-27
Primary Completion 2026-04 (estimated)
Study Completion 2031-04 (estimated)
Updated on ClinicalTrials.gov 2025-08-14